Core Viewpoint - Qiming Medical-B (02500) announced a share transfer agreement where Qiming Medical (Hong Kong) Limited will sell shares to Broncus China Holding Corporation for $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] Group 1: Investment Details - The transaction involves the sale of shares for a total consideration of $15 million [1] - The investment company Valgen Holding Corporation is registered and incorporated under Cayman Islands law and primarily provides systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Focus - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - As a minority financial investor in Valgen, the sale represents an appropriate opportunity for the group to monetize its investment [1] - By divesting non-core business investments, the group expects to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Capital Management - The board believes that prudent capital management, including this sale, is beneficial for ensuring the sustainable development of the group and enhancing shareholder returns [1]
启明医疗-B(02500)拟1500万美元出售被投资公司Valgen Holding Corporation约1.05%股份